A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Latest Information Update: 19 Nov 2024
At a glance
- Drugs Batoclimab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms ASCEND-MG
- Sponsors Immunovant
Most Recent Events
- 16 Feb 2021 Status changed from recruiting to completed.
- 25 Aug 2020 Top-line results are presented in an Immunovant media release.
- 25 Aug 2020 Results presented in a Ligand Pharmaceuticals Media Release.